Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:sulfonate
go back to main search page
Accession:CHEBI:33543 term browser browse the term
Definition:The sulfur oxoanion formed by deprotonation of sulfonic acid.
Synonyms:exact_synonym: hydridotrioxidosulfate(1-)
 related_synonym: Formula=HO3S;   InChI=1S/H2O3S/c1-4(2)3/h4H,(H,1,2,3)/p-1;   InChIKey=BDHFUVZGWQCTTF-UHFFFAOYSA-M;   SHO3(-);   SMILES=[H]S([O-])(=O)=O;   sulfonates
 xref: Gmelin:971569
 cyclic_relationship: is_conjugate_base_of CHEBI:29214



show annotations for term's descendants           Sort by:
acid red 29 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ALB albumin affects binding EXP chromotrope 2R binds to ALB protein CTD PMID:19347248 NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
JBrowse link
benzenesulfonates term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC10A1 solute carrier family 10 member 1 multiple interactions EXP Benzenesulfonates analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid] CTD PMID:22641618 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
Congo Red term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G APP amyloid beta precursor protein multiple interactions
affects binding
ISO
EXP
Congo Red inhibits the reaction [APP protein binds to APP protein]
Congo Red binds to APP protein
CTD PMID:17323972 PMID:17406451 NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
JBrowse link
G PRNP prion protein (Kanno blood group) decreases expression ISO Congo Red results in decreased expression of PRNP protein alternative form CTD PMID:11994310 NCBI chr20:4,686,456...4,701,588
Ensembl chr20:4,686,350...4,701,590
JBrowse link
Fast green FCF term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G IYD iodotyrosine deiodinase multiple interactions EXP Fast Green FCF inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] CTD PMID:33352258 NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969
JBrowse link
indigo carmine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AHR aryl hydrocarbon receptor multiple interactions
affects binding
EXP
ISO
Indigo Carmine binds to and results in increased activity of AHR protein
Indigo Carmine binds to AHR protein
CTD PMID:11425848 PMID:15001395 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
JBrowse link
G CHRNA4 cholinergic receptor nicotinic alpha 4 subunit multiple interactions ISO [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein CTD PMID:23429044 NCBI chr20:63,343,223...63,361,349
Ensembl chr20:63,343,223...63,378,401
JBrowse link
G CHRNB2 cholinergic receptor nicotinic beta 2 subunit multiple interactions ISO [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of CHRNB2 protein CTD PMID:23429044 NCBI chr 1:154,567,778...154,580,013
Ensembl chr 1:154,567,778...154,580,013
JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 increases activity
increases expression
multiple interactions
EXP
ISO
Indigo Carmine results in increased activity of CYP1A1 protein
Indigo Carmine results in increased expression of CYP1A1 mRNA
Indigo Carmine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
CTD PMID:15001395 PMID:15882963 PMID:18493746 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
JBrowse link
G GRIN2A glutamate ionotropic receptor NMDA type subunit 2A multiple interactions ISO [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of GRIN2A protein; [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of GRIN2A protein CTD PMID:23429044 NCBI chr16:9,753,404...10,182,908
Ensembl chr16:9,753,404...10,183,337
JBrowse link
indocyanine green term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions
decreases activity
EXP Indocyanine Green inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Indocyanine Green results in decreased activity of ABCB11 protein
CTD PMID:24014644 NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCB4 ATP binding cassette subfamily B member 4 affects export ISO ABCB4 protein affects the export of Indocyanine Green CTD PMID:11302927 NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
JBrowse link
G BAX BCL2 associated X, apoptosis regulator increases expression EXP Indocyanine Green results in increased expression of BAX mRNA; Indocyanine Green results in increased expression of BAX protein CTD PMID:23675521 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G CASP9 caspase 9 increases expression EXP Indocyanine Green results in increased expression of CASP9 mRNA; Indocyanine Green results in increased expression of CASP9 protein CTD PMID:23675521 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G SLC10A1 solute carrier family 10 member 1 multiple interactions
increases uptake
EXP Nifedipine promotes the reaction [SLC10A1 protein results in increased uptake of Indocyanine Green]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased uptake of Indocyanine Green] CTD PMID:32209977 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC10A2 solute carrier family 10 member 2 increases uptake EXP SLC10A2 protein results in increased uptake of Indocyanine Green CTD PMID:32209977 NCBI chr13:103,043,998...103,066,417
Ensembl chr13:103,043,998...103,066,417
JBrowse link
G SLC16A2 solute carrier family 16 member 2 multiple interactions EXP Indocyanine Green inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine] CTD PMID:28119167 NCBI chr  X:74,421,493...74,533,916
Ensembl chr  X:74,421,493...74,533,917
JBrowse link
G SLC22A7 solute carrier family 22 member 7 multiple interactions ISO Indocyanine Green inhibits the reaction [SLC22A7 protein results in increased uptake of Glutarates] CTD PMID:12065749 NCBI chr 6:43,295,714...43,305,538
Ensembl chr 6:43,295,694...43,305,538
JBrowse link
G SLC22A8 solute carrier family 22 member 8 multiple interactions ISO Indocyanine Green inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate] CTD PMID:10224140 NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
JBrowse link
lucifer yellow dye term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCG2 ATP binding cassette subfamily G member 2 (JR blood group) multiple interactions
increases uptake
increases transport
EXP 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [ABCG2 protein results in increased uptake of lucifer yellow]; Novobiocin inhibits the reaction [ABCG2 protein results in increased uptake of lucifer yellow]; Omeprazole inhibits the reaction [ABCG2 protein results in increased transport of lucifer yellow] CTD PMID:31348918 PMID:32305507 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
JBrowse link
metamizole sodium term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CRH corticotropin releasing hormone multiple interactions ISO Dipyrone inhibits the reaction [IL1B protein results in increased secretion of CRH protein]; Dipyrone inhibits the reaction [IL6 protein results in increased secretion of CRH protein]; Dipyrone inhibits the reaction [Lipopolysaccharides results in increased secretion of CRH protein]; Dipyrone inhibits the reaction [TNF protein results in increased secretion of CRH protein] CTD PMID:11852909 NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464
JBrowse link
G EGFR epidermal growth factor receptor multiple interactions ISO Dipyrone promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein] CTD PMID:15309881 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
JBrowse link
G IL1B interleukin 1 beta multiple interactions ISO Dipyrone inhibits the reaction [IL1B protein results in increased secretion of CRH protein] CTD PMID:11852909 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
JBrowse link
G IL6 interleukin 6 multiple interactions ISO Dipyrone inhibits the reaction [IL6 protein results in increased secretion of CRH protein] CTD PMID:11852909 NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
JBrowse link
G PTGS1 prostaglandin-endoperoxide synthase 1 decreases activity EXP
ISO
Dipyrone analog results in decreased activity of PTGS1 protein; Dipyrone results in decreased activity of PTGS1 protein CTD PMID:12242329 PMID:16141368 NCBI chr 9:122,370,533...122,395,703
Ensembl chr 9:122,370,530...122,395,703
JBrowse link
G TGFA transforming growth factor alpha multiple interactions ISO Dipyrone promotes the reaction [Hydrochloric Acid results in increased expression of TGFA protein] CTD PMID:15309881 NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193
JBrowse link
G TNF tumor necrosis factor multiple interactions ISO Dipyrone inhibits the reaction [TNF protein results in increased secretion of CRH protein] CTD PMID:11852909 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link
Sirius red 4B term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G IYD iodotyrosine deiodinase multiple interactions EXP Direct Red 81 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] CTD PMID:33352258 NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969
JBrowse link
sodium taurocholate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G IL17A interleukin 17A increases expression ISO Sodium taurocholate increases expression of Il17a mRNA and protein in the pancreas RGD PMID:22990529 RGD:9068935 NCBI chr 6:52,186,375...52,190,638
Ensembl chr 6:52,186,375...52,190,638
JBrowse link
tartrazine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA CTD PMID:33819548 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
JBrowse link
G ABCB4 ATP binding cassette subfamily B member 4 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA CTD PMID:33819548 NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 (ABCC1 blood group) multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA CTD PMID:33819548 NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA CTD PMID:33819548 NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA CTD PMID:33819548 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 (PEL blood group) multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA CTD PMID:33819548 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (JR blood group) multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA CTD PMID:33819548 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
JBrowse link
G ABCG5 ATP binding cassette subfamily G member 5 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA CTD PMID:33819548 NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865
JBrowse link
G ABCG8 ATP binding cassette subfamily G member 8 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA CTD PMID:33819548 NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
JBrowse link
G ADGRG1 adhesion G protein-coupled receptor G1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA CTD PMID:33819548 NCBI chr16:57,619,738...57,665,567
Ensembl chr16:57,610,652...57,665,580
JBrowse link
G ADH1C alcohol dehydrogenase 1C (class I), gamma polypeptide multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA CTD PMID:33819548 NCBI chr 4:99,336,497...99,352,746
Ensembl chr 4:99,336,497...99,352,746
JBrowse link
G ADH4 alcohol dehydrogenase 4 (class II), pi polypeptide multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA CTD PMID:33819548 NCBI chr 4:99,123,658...99,144,297
Ensembl chr 4:99,123,657...99,157,792
JBrowse link
G ADH6 alcohol dehydrogenase 6 (class V) multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA CTD PMID:33819548 NCBI chr 4:99,202,639...99,219,246
Ensembl chr 4:99,202,638...99,219,537
JBrowse link
G AKR1C4 aldo-keto reductase family 1 member C4 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1C4 mRNA CTD PMID:33819548 NCBI chr10:5,196,837...5,218,949
Ensembl chr10:5,195,462...5,218,949
JBrowse link
G AKR1D1 aldo-keto reductase family 1 member D1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA CTD PMID:33819548 NCBI chr 7:138,076,459...138,118,305
Ensembl chr 7:138,002,324...138,118,305
JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA CTD PMID:33819548 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,301,991...19,312,144
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA CTD PMID:33819548 NCBI chr 1:19,274,229...19,288,770
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G ALB albumin multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA CTD PMID:33819548 NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
JBrowse link
G AMPD3 adenosine monophosphate deaminase 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA CTD PMID:33819548 NCBI chr11:10,450,388...10,507,579
Ensembl chr11:10,308,313...10,507,579
JBrowse link
G APOA1 apolipoprotein A1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA CTD PMID:33819548 NCBI chr11:116,835,751...116,837,622
Ensembl chr11:116,835,751...116,837,622
JBrowse link
G ATP8B1 ATPase phospholipid transporting 8B1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA CTD PMID:33819548 NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315
JBrowse link
G BAAT bile acid-CoA:amino acid N-acyltransferase multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA CTD PMID:33819548 NCBI chr 9:101,360,417...101,385,006
Ensembl chr 9:101,354,182...101,385,400
JBrowse link
G BACH1 BTB domain and CNC homolog 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA CTD PMID:33819548 NCBI chr21:29,298,922...29,361,894
Ensembl chr21:29,194,071...29,630,751
JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA CTD PMID:33819548 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
JBrowse link
G CASP9 caspase 9 multiple interactions ISO [Tartrazine co-treated with Erythrosine] affects the expression of CASP9 mRNA CTD PMID:32981412 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CAT catalase decreases activity
multiple interactions
ISO
EXP
Tartrazine results in decreased activity of CAT protein
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA
CTD PMID:20678534 PMID:33819548 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CHRNA4 cholinergic receptor nicotinic alpha 4 subunit multiple interactions ISO [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein CTD PMID:23429044 NCBI chr20:63,343,223...63,361,349
Ensembl chr20:63,343,223...63,378,401
JBrowse link
G CHRNB2 cholinergic receptor nicotinic beta 2 subunit multiple interactions ISO [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of CHRNB2 protein CTD PMID:23429044 NCBI chr 1:154,567,778...154,580,013
Ensembl chr 1:154,567,778...154,580,013
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA CTD PMID:33819548 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CXCL8 mRNA CTD PMID:33819548 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
JBrowse link
G CYP2A6 cytochrome P450 family 2 subfamily A member 6 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2A6 mRNA CTD PMID:33819548 NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA CTD PMID:33819548 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP2C18 cytochrome P450 family 2 subfamily C member 18 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA CTD PMID:33819548 NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190
JBrowse link
G CYP2C9 cytochrome P450 family 2 subfamily C member 9 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C9 mRNA CTD PMID:33819548 NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA CTD PMID:33819548 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP3A5 cytochrome P450 family 3 subfamily A member 5 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA CTD PMID:33819548 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G CYP7B1 cytochrome P450 family 7 subfamily B member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA CTD PMID:33819548 NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737
JBrowse link
G CYP8B1 cytochrome P450 family 8 subfamily B member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA CTD PMID:33819548 NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA CTD PMID:33819548 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA CTD PMID:33819548 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,255...182,794,464
JBrowse link
G DNAJC18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA CTD PMID:33819548 NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA CTD PMID:33819548 NCBI chr10:73,232,272...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G EIF2AK3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA CTD PMID:33819548 NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518
JBrowse link
G ESR1 estrogen receptor 1 increases activity
multiple interactions
EXP Tartrazine results in increased activity of ESR1 protein
fulvestrant inhibits the reaction [Tartrazine results in increased activity of ESR1 protein]
CTD PMID:22562034 NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA CTD PMID:33819548 NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FTH1 ferritin heavy chain 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA CTD PMID:33819548 NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634
JBrowse link
G GCLM glutamate-cysteine ligase modifier subunit multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA CTD PMID:33819548 NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456
JBrowse link
G GJB2 gap junction protein beta 2 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA CTD PMID:33819548 NCBI chr13:20,187,470...20,192,938
Ensembl chr13:20,187,463...20,192,938
JBrowse link
G GPRC5B G protein-coupled receptor class C group 5 member B multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA CTD PMID:33819548 NCBI chr16:19,856,691...19,885,634
Ensembl chr16:19,856,691...19,886,167
JBrowse link
G GRIN2A glutamate ionotropic receptor NMDA type subunit 2A multiple interactions ISO [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of GRIN2A protein; [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of GRIN2A protein CTD PMID:23429044 NCBI chr16:9,753,404...10,182,908
Ensembl chr16:9,753,404...10,183,337
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA CTD PMID:33819548 NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA3 mRNA CTD PMID:33819548 NCBI chr 6:52,896,646...52,909,698
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTA4 glutathione S-transferase alpha 4 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA CTD PMID:33819548 NCBI chr 6:52,977,953...52,995,284
Ensembl chr 6:52,977,948...52,995,304
JBrowse link
G GSTT1 glutathione S-transferase theta 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA CTD PMID:33819548
G HAVCR1 hepatitis A virus cellular receptor 1 multiple interactions ISO [Tartrazine co-treated with Erythrosine] affects the expression of HAVCR1 mRNA CTD PMID:32981412 NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396
JBrowse link
G HPX hemopexin multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA CTD PMID:33819548 NCBI chr11:6,431,049...6,440,987
Ensembl chr11:6,431,049...6,442,617
JBrowse link
G IFI16 interferon gamma inducible protein 16 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI16 mRNA CTD PMID:33819548 NCBI chr 1:158,999,976...159,055,151
Ensembl chr 1:158,999,968...159,055,155
JBrowse link
G IFI27 interferon alpha inducible protein 27 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA CTD PMID:33819548 NCBI chr14:94,105,894...94,116,690
Ensembl chr14:94,104,836...94,116,695
JBrowse link
G IL1R1 interleukin 1 receptor type 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA CTD PMID:33819548 NCBI chr 2:102,070,390...102,179,874
Ensembl chr 2:102,064,544...102,179,874
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA CTD PMID:33819548 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
JBrowse link
G LIPC lipase C, hepatic type multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA CTD PMID:33819548 NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844
JBrowse link
G LY96 lymphocyte antigen 96 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA CTD PMID:33819548 NCBI chr 8:73,991,392...74,099,857
Ensembl chr 8:73,991,392...74,029,079
JBrowse link
G MAF MAF bZIP transcription factor multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA CTD PMID:33819548 NCBI chr16:79,202,622...79,600,737
Ensembl chr16:79,585,843...79,600,737
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA CTD PMID:33819548 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA CTD PMID:33819548 NCBI chr19:4,090,321...4,124,122
Ensembl chr19:4,090,321...4,124,122
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA CTD PMID:33819548 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAP3K5 mitogen-activated protein kinase kinase kinase 5 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA CTD PMID:33819548 NCBI chr 6:136,557,046...136,793,091
Ensembl chr 6:136,557,046...136,793,097
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA CTD PMID:33819548 NCBI chr 3:50,611,520...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MGST1 microsomal glutathione S-transferase 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA CTD PMID:33819548 NCBI chr12:16,347,115...16,593,331
Ensembl chr12:16,347,142...16,609,259
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA CTD PMID:33819548 NCBI chr16:74,671,855...74,700,862
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G MMUT methylmalonyl-CoA mutase multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA CTD PMID:33819548 NCBI chr 6:49,430,360...49,463,253
Ensembl chr 6:49,430,360...49,463,253
JBrowse link
G MTTP microsomal triglyceride transfer protein multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA CTD PMID:33819548 NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997
JBrowse link
G NR0B2 nuclear receptor subfamily 0 group B member 2 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA CTD PMID:33819548 NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA CTD PMID:33819548 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA CTD PMID:33819548 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA CTD PMID:33819548 NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
JBrowse link
G PAH phenylalanine hydroxylase multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA CTD PMID:33819548 NCBI chr12:102,836,889...102,958,441
Ensembl chr12:102,836,889...102,958,410
JBrowse link
G PIK3C2A phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA CTD PMID:33819548 NCBI chr11:17,086,575...17,207,986
Ensembl chr11:17,077,730...17,207,986
JBrowse link
G PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA CTD PMID:33819548 NCBI chr12:18,242,961...18,726,817
Ensembl chr12:18,242,961...18,648,416
JBrowse link
G PIK3R3 phosphoinositide-3-kinase regulatory subunit 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA CTD PMID:33819548 NCBI chr 1:46,040,140...46,174,901
Ensembl chr 1:46,040,140...46,133,036
JBrowse link
G PPP1R3C protein phosphatase 1 regulatory subunit 3C multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA CTD PMID:33819548 NCBI chr10:91,628,442...91,633,071
Ensembl chr10:91,628,442...91,633,071
JBrowse link
G PRKD3 protein kinase D3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA CTD PMID:33819548 NCBI chr 2:37,250,502...37,324,833
Ensembl chr 2:37,250,502...37,324,833
JBrowse link
G RARA retinoic acid receptor alpha multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA CTD PMID:33819548 NCBI chr17:40,309,180...40,357,643
Ensembl chr17:40,309,180...40,357,643
JBrowse link
G RASD1 ras related dexamethasone induced 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA CTD PMID:33819548 NCBI chr17:17,494,437...17,496,395
Ensembl chr17:17,494,437...17,496,395
JBrowse link
G RDH16 retinol dehydrogenase 16 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA CTD PMID:33819548 NCBI chr12:56,951,431...56,957,608
Ensembl chr12:56,951,431...56,959,374
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA CTD PMID:33819548 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SLC10A1 solute carrier family 10 member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA CTD PMID:33819548 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC22A1 solute carrier family 22 member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA CTD PMID:33819548 NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLCO1B1 mRNA CTD PMID:33819548 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA CTD PMID:33819548 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SORL1 sortilin related receptor 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA CTD PMID:33819548 NCBI chr11:121,452,314...121,633,763
Ensembl chr11:121,452,314...121,633,763
JBrowse link
G SREBF1 sterol regulatory element binding transcription factor 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA CTD PMID:33819548 NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA CTD PMID:33819548 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
JBrowse link
G TFF1 trefoil factor 1 multiple interactions
increases expression
EXP fulvestrant inhibits the reaction [Tartrazine results in increased expression of TFF1 mRNA] CTD PMID:22562034 NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535
JBrowse link
G TLR3 toll like receptor 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA CTD PMID:33819548 NCBI chr 4:186,069,156...186,088,073
Ensembl chr 4:186,068,911...186,088,073
JBrowse link
G TLR4 toll like receptor 4 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA CTD PMID:33819548 NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
JBrowse link
G TNF tumor necrosis factor multiple interactions ISO [Tartrazine co-treated with Erythrosine] results in increased expression of TNF mRNA CTD PMID:32981412 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link
G TNFRSF9 TNF receptor superfamily member 9 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA CTD PMID:33819548 NCBI chr 1:7,915,871...7,940,839
Ensembl chr 1:7,915,871...7,943,165
JBrowse link
G TNFSF10 TNF superfamily member 10 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA CTD PMID:33819548 NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
JBrowse link
G TNFSF11 TNF superfamily member 11 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA CTD PMID:33819548 NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
JBrowse link
G UGT2B4 UDP glucuronosyltransferase family 2 member B4 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of UGT2B4 mRNA CTD PMID:33819548 NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26503
    chemical entity 26483
      atom 26479
        nonmetal atom 25742
          sulfur atom 20394
            sulfur molecular entity 20394
              sulfur oxoanion 722
                sulfonate 120
                  organosulfonate oxoanion + 120
                  sulfonato group 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 26503
    subatomic particle 26479
      composite particle 26479
        hadron 26479
          baryon 26479
            nucleon 26479
              atomic nucleus 26479
                atom 26479
                  main group element atom 26217
                    p-block element atom 26217
                      chalcogen 25128
                        oxygen atom 24935
                          oxygen molecular entity 24935
                            oxide 13916
                              oxoanion 11025
                                chalcogen oxoanion 724
                                  sulfur oxoanion 722
                                    sulfonate 120
                                      organosulfonate oxoanion + 120
                                      sulfonato group 0
paths to the root